Ausgewählte Studien

Original Paper Background: Psoriasis (PsO) is a chronic, systemic, immune-mediated disease with multiorgan involvement. Psoriatic arthritis (PsA) is …Den ganzen Artikel lesen

J Dtsch Dermatol Ges. 2024 Apr;22(4):577-579. doi: 10.1111/ddg.15338_g. NO ABSTRACT PMID:38574004 | DOI:10.1111/ddg.15338_g Den ganzen Artikel lesen

J Dtsch Dermatol Ges. 2023 Nov;21(11):1351-1358. doi: 10.1111/ddg.15191_g. ABSTRACT HINTERGRUND UND ZIELSETZUNG: Die Psoriasisarthritis (PsA) erfordert für bestmögliche therapeutische Ergebnisse eine frühzeitige Diagnose und den Einsatz adäquater antirheumatischer Therapien sowie der regelmäßigen Überprüfung des Therapieerfolges. Ziel dieser Studie war es, die routinemäßigen Überwachungsmaßnahmen für Patienten mit gesicherter PsA und Psoriasis vulgaris (PsO) durch Dermatologen zu untersuchen und

J Eur Acad Dermatol Venereol. 2024 Apr 4. doi: 10.1111/jdv.19974. Online ahead of print. ABSTRACT BACKGROUND: Brodalumab, a fully human monoclonal immunoglobulin IgG2 antibody that binds the human interleukin 17 receptor subunit A, is available for the treatment of moderate-to-severe plaque psoriasis in Europe since September 2017, but so far there are only a few studies on its use in real-world conditions. OBJECTIVES: To assess the management of moderate-to-severe psoriasis with brodalumab 210

Background: Brodalumab, a fully human monoclonal immunoglobulin IgG2 antibody that binds the human interleukin 17 receptor subunit A, is available …Den ganzen Artikel lesen

J Dtsch Dermatol Ges. 2023 Nov;21(11):1351-1357. doi: 10.1111/ddg.15191. Epub 2023 Oct 9. ABSTRACT BACKGROUND AND OBJECTIVES: Psoriatic arthritis (PsA) warrants early diagnosis and treatment for optimal results. This study aimed to elucidate routine monitoring activities for PsA with concurrent psoriasis (PsO) by dermatologists to gather data on how conditions for optimal treatment are ensured. PATIENTS AND METHODS: This non-interventional, prospective, epidemiological, cross-sectional study (20

SummaryBackground and ObjectivesPsoriatic arthritis (PsA) warrants early diagnosis and treatment for optimal results. This study aimed to elucidate …Den ganzen Artikel lesen

Actas Dermosifiliogr. 2020 Nov;111(9):802-804. doi: 10.1016/j.adengl.2020.05.001. Epub 2020 Oct 16. NO ABSTRACT PMID:34012158 | PMC:PMC7566662 | DOI:10.1016/j.adengl.2020.05.001 Den ganzen Artikel lesen

Drugs. 2023 Mar 28. doi: 10.1007/s40265-023-01857-w. Online ahead of print. ABSTRACT Axial symptoms (i.e., back pain) are common in the general population. At the same time 25-70% of patients with psoriatic arthritis (PsA) exhibit signs of inflammatory axial involvement (axial PsA). The presence of unexplained chronic (duration ≥ 3 months) back pain in a patient with psoriasis or PsA should trigger evaluation of the presence of axial involvement. Evaluation of axial involvement normally involves

Background: The diagnosis of psoriasis may be missed or delayed in primary care settings. Aim: To examine trends in healthcare events before a …Den ganzen Artikel lesen

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly being used to treat diabetes and obesity. However, their effectiveness and …Den ganzen Artikel lesen

Key Points Question What potentially driver-impairing medications are associated with poor road test performance over time? Findings In this cohort …Den ganzen Artikel lesen

1. Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: a literature review. Best Pract Res Clin Rheumatol 2021; 35(2): …Den ganzen Artikel lesen

Background: The role of methotrexate in combination with biological agents in patients with psoriatic arthritis remains unclear. The MUST phase 3b …Den ganzen Artikel lesen

Int J Pharm. 2022 Apr 25;618:121693. doi: 10.1016/j.ijpharm.2022.121693. Epub 2022 Mar 21. ABSTRACT Psoriasis is a condition of the skin which involves scales, dry patches, and inflammation. Methotrexate (logP: -1.8, MW:454.44 g/mol) is administered orally or intravenously to treat psoriasis. The first-pass metabolism and systemic toxicity can be avoided by administration via skin. Topical and transdermal delivery of methotrexate using iontophoresis and microneedles, alone and in combination was

Pharm Res. 2022 Feb 16. doi: 10.1007/s11095-022-03190-5. Online ahead of print. ABSTRACT PURPOSE: To investigate in vitro transdermal delivery of tofacitinib citrate across human skin using microporation by microneedles and iontophoresis alone and in combination. METHODS: In vitro permeation studies were conducted using vertical Franz diffusion cells. Microneedles composed of polyvinyl alcohol and carboxymethyl cellulose were fabricated and successfully characterized using scanning electron micr

Medical Advisory Secretariat. Medical Advisory Secretariat. Ont Health Technol Assess Ser. 2009;9(27):1-66. Epub 2009 Nov 1. Ont Health Technol …Den ganzen Artikel lesen

Methotrexate is successfully used as the gold standard for managing moderate-to-severe psoriasis. However, the low bioavailability and short …Den ganzen Artikel lesen

J Dtsch Dermatol Ges. 2021 Dec;19(12):1736-1745. doi: 10.1111/ddg.14606_g. ABSTRACT Hintergrund: Die Psoriasis gilt als unabhängiger kardiovaskulärer Risikofaktor und Treiber einer Atherogenese. Mikrovaskuläre Veränderungen in psoriatischen Plaques sind gut beschrieben, wohingegen Veränderungen außerhalb betroffener Hautareale kaum untersucht wurden. In dieser Studie wurden Nagelfalzkapillaren von Psoriasispatienten in nicht betroffener Haut systematisch untersucht. Patienten und Methodik: Prosp

Actas Dermosifiliogr. 2023 May 25:S0001-7310(23)00397-6. doi: 10.1016/j.ad.2023.05.016. Online ahead of print. ABSTRACT Managing moderate to severe psoriasis in older adults is complex due to factors characteristic of the later years of life, such as associated comorbidity, polypharmacy, and immunosenescence. This consensus statement discusses 17 recommendations for managing treatment for moderate to severe psoriasis in patients older than 65 years. The recommendations were proposed by a committ

Actas Dermosifiliogr. 2021 Sep 24:S0001-7310(21)00342-2. doi: 10.1016/j.ad.2021.05.017. Online ahead of print. ABSTRACT Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoriasis in the BIOBADADERM registry and to analyze the characteristics of these patients, treatments u

Background: Although the inclusion of patients' preferences and needs is essential for therapy adherence, the assessment of patient-reported outcome …Den ganzen Artikel lesen

Dermatol Ther (Heidelb). 2021 Sep 24. doi: 10.1007/s13555-021-00606-9. Online ahead of print. ABSTRACT INTRODUCTION: There is limited and conflicting evidence over the real-world drug survival of secukinumab (SEC) in patients with psoriasis, especially in the long term. Our objective was to analyze the short- and long-term survival of SEC (S-SEC) and its predictive factors for the treatment of psoriasis. METHODS: Patients clinically diagnosed with plaque psoriasis and under treatment with secuk

Background: Co-existing long-term conditions (LTC) in psoriasis and their potential causal associations with the disease are not …Den ganzen Artikel lesen

Int J Womens Dermatol . 2024 Nov 15;10(4):e187. doi: 10.1097/JW9.0000000000000187 Brigitte Stephan, MD a Institute for Health Services Research in …Den ganzen Artikel lesen